Genmab to Showcase Latest Blood Cancer Treatment Advancements at 2025 American Society of Hematology (ASH) Annual Meeting

Core Insights - Genmab A/S announced the presentation of over 20 abstracts on epcoritamab, a T-cell engaging bispecific antibody, at the upcoming American Society of Hematology (ASH) meeting, highlighting its potential in treating various B-cell non-Hodgkin's lymphoma subtypes [2][4]. Clinical Data and Presentations - The data from the epcoritamab development program will demonstrate its expanding clinical profile, particularly in earlier lines of therapy with a fixed treatment duration [3][7]. - Key presentations will include oral sessions on the efficacy of epcoritamab in first- and second-line settings for follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) [3][7]. - The Phase 3 EPCORE FL-1 trial results, evaluating epcoritamab in combination with rituximab and lenalidomide for relapsed or refractory FL, will be shared [4][7]. Event Details - Genmab will host a virtual 2025 R&D Update and ASH Data Review on December 11, 2025, to discuss the findings further [5]. - All abstracts accepted for presentation have been published and are accessible on the ASH website [6]. Abstract Highlights - The abstracts include significant findings such as high response rates and minimal residual disease (MRD) negativity in elderly patients with newly diagnosed LBCL [6][9]. - Additional presentations will cover the long-term efficacy of epcoritamab in various treatment combinations and settings, including its use as monotherapy for patients with Richter transformation [8][9]. Company Overview - Genmab is focused on developing epcoritamab as a core therapy for a range of B-cell malignancies, showcasing its commitment to advancing treatment options in hematologic cancers [4][14]. - The company is co-developing epcoritamab with AbbVie, sharing commercial responsibilities in the U.S. and Japan, while pursuing further global regulatory approvals [14][15].